Who are Regeneron Casirivimab + Imdevimab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casirivimab and Imdevimab Drug Combination, COVID-19 mRNA vaccine, batch 3 of Ad5-nCoV, mRNA-1273 Variant-containing Formulation, protein subunit: Novavax COVID-19 vaccine, COMIRNATY intramuscular injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/regeneron-casirivimab-imdevimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Regeneron Casirivimab + Imdevimab — Competitive Intelligence Brief

Regeneron Casirivimab + Imdevimab (Regeneron Casirivimab + Imdevimab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody combination (neutralizing antibodies). Area: Infectious Disease / Virology.

marketed Monoclonal antibody combination (neutralizing antibodies) SARS-CoV-2 spike protein Infectious Disease / Virology Biologic Live · refreshed every 30 min

Target snapshot

Regeneron Casirivimab + Imdevimab (Regeneron Casirivimab + Imdevimab) — Erin McCreary. This combination of two monoclonal antibodies binds to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection of human cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Regeneron Casirivimab + Imdevimab TARGET	Regeneron Casirivimab + Imdevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
batch 3 of Ad5-nCoV	batch 3 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
protein subunit: Novavax COVID-19 vaccine	protein subunit: Novavax COVID-19 vaccine	Novavax	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
COMIRNATY intramuscular injection	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody combination (neutralizing antibodies) class)

Erin McCreary · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Regeneron Casirivimab + Imdevimab — Competitive Intelligence Brief. https://druglandscape.com/ci/regeneron-casirivimab-imdevimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab